Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.
Saved in:
| Title: | Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML. |
|---|---|
| Authors: | Wang Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Skwarska A; Department of Medicine (Oncology), Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY., Poigaialwar G; Department of Medicine (Oncology), Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY., Chaudhry S; Department of Medicine (Oncology), Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY., Rodriguez-Meira A; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA., Sui P; Department of Cell Systems and Anatomy, The University of Texas Health Science Center at San Antonio, San Antonio, TX., Olivier E; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.; Center for the Advancement of Blood Cancer Therapies, Institute for Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY., Jia Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Gupta V; Department of Medicine (Oncology), Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY., Fiskus W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ramage CL; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Zheng G; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL., Schurer A; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY., Gritsman K; Department of Medicine (Oncology), Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY.; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY., Papapetrou EP; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.; Center for the Advancement of Blood Cancer Therapies, Institute for Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY., Bhalla K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Zhou D; Department of Biochemistry and Structural Biology and Center for Innovative Drug Discovery, The University of Texas Health Science Center at San Antonio, San Antonio, TX., Mead AJ; Haematopoietic Stem Cell Biology Laboratory, Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom., Rampal RK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Tyner JW; Department of Cell, Developmental, and Cancer Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR., Abbas HA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Tatarata QZ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Internal Medicine Department, New York City Health + Hospitals/Kings County Hospital, State University of New York Downstate Health Sciences University, Brooklyn, NY., Konopleva M; Department of Medicine (Oncology), Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY. |
| Source: | Blood [Blood] 2025 Jul 17; Vol. 146 (3), pp. 341-355. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
